文献速递生殖医学

青春期抑制与激素治疗对跨性别女性发育中生殖细胞影响的组织学研究

Histological study on the influence of puberty suppression and hormonal treatment on developing germ cells in transgender women.
PubMed 文献 · Hum Reprod · 2022-01-01

该研究对2006至2018年间接受生殖器性别肯定手术的214例跨性别女性的睾丸切除标本进行组织学和免疫组化分析,按医疗干预启动时的Tanner分期及术前是否暂停激素治疗分为6个亚组。结果显示4.7%的标本存在成熟精子,均来自Tanner 4期及以上启动治疗者;88.3%仅含未成熟生殖细胞,7.0%完全无生殖细胞且均来自成年期启动治疗者。术前暂停激素治疗及激素治疗时长均不影响生殖细胞的存在或成熟阶段。

要点

  • 4.7%的睾丸切除标本存在成熟精子,均来自Tanner 4期及以上启动医疗干预的跨性别女性。
  • 88.3%的标本仅含未成熟生殖细胞,7.0%完全无生殖细胞且均来自成年期启动治疗者。
  • 术前暂停激素治疗及激素治疗时长均不影响生殖细胞的存在或成熟阶段。

核心结论

  • 绝大多数跨性别女性的睾丸切除标本中仍存在未成熟生殖细胞,4.7%存在成熟精子,均来自Tanner 4期及以上启动医疗干预者,可能实现精子或睾丸组织冷冻保存。

研究设计与样本

  • 对2006至2018年间接受生殖器性别肯定手术的214例跨性别女性的睾丸切除标本进行组织学和免疫组化分析。
  • 根据医疗干预启动时的青春期阶段(Tanner 2-3期、Tanner 4-5期、成年)及术前是否继续或暂停激素治疗,分为6个亚组。
  • 所有跨性别女性均使用雌激素联合睾酮抑制治疗。
  • 采用MAGE-A3/A4、γH2AX、Acrosin标记物通过免疫组化验证组织学发现。
  • 采用逻辑回归分析激素治疗时长与生育力保存可能性之间的关联。

主要发现

  • 4.7%的睾丸切除标本存在成熟精子,全部来自Tanner 4期及以上启动医疗干预的跨性别女性。
  • 88.3%的标本仅含未成熟生殖细胞,以圆形精子细胞、精母细胞或精原细胞为最成熟类型。
  • 7.0%的标本完全无生殖细胞,全部来自成年期启动医疗干预的跨性别女性。
  • 术前暂停激素治疗不影响生殖细胞的存在或成熟阶段,激素治疗时长对生殖细胞也无影响。

局限性

  • 由于缺乏生殖器性别肯定手术当日的血清激素水平数据,无法核实被要求术前4周暂停激素治疗的跨性别女性是否实际执行,也无法确认完全精子生成者是否依从治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can transgender women cryopreserve germ cells obtained from their orchiectomy specimen for fertility preservation, after having used puberty suppression and/or hormonal treatment? SUMMARY ANSWER: In the vast majority of transgender women, there were still immature germ cells present in the orchiectomy specimen, and in 4.7% of transgender women-who all initiated medical treatment in Tanner stage 4 or higher-mature spermatozoa were found, which would enable cryopreservation of spermatozoa or testicular tissue after having used puberty suppression and/or hormonal treatment. WHAT IS KNOWN ALREADY: Gender affirming treatment (i.e. puberty suppression, hormonal treatment, and subsequent orchiectomy) impairs reproductive function in transgender women. Although semen cryopreservation is generally offered during the transition process, this option is not feasible for all transgender women (e.g. due to incomplete spermatogenesis when initiating treatment in early puberty, in case of inability to masturbate, or when temporary cessation of hormonal treatment is too disruptive). Harvesting mature spermatozoa, or testicular tissue harboring immature germ cells, from orchiectomy specimens obtained during genital gender-affirming surgery (gGAS) might give this group a chance of having biological children later in life. Previous studies on spermatogenesis in orchiectomy specimens showed conflicting results, ranging from complete absence of germ cells to full spermatogenesis, and did not involve transgender women who initiated medical treatment in early- or late puberty. STUDY DESIGN, SIZE, DURATION: Histological and immunohistochemical analyses were performed on orchiectomy specimens from 214 transgender women who underwent gGAS between 2006 and 2018. Six subgroups were identified, depending on pubertal stage at initiation of medical treatment (Tanner stage 2-3, Tanner stage 4-5, adult), and whether hormonal treatment was continued or temporarily stopped prior to gGAS in each of these groups. PARTICIPANTS/MATERIALS, SETTING, METHODS: All transgender women used a combination of estrogens and testosterone suppressing therapy. Orchiectomy specimen sections were stained with Mayer's hematoxylin and eosin and histologically analyzed to assess the Johnsen score and the ratio of most advanced germ cell types in at least 50 seminiferous tubular cross-sections. Subsequently, immunohistochemistry was used to validate these findings using spermatogonia, spermatocytes or spermatids markers (MAGE-A3/A4, γH2AX, Acrosin, respectively). Possibilities for fertility preservation were defined as: preservation of spermatozoa, preservation of spermatogonial stem cells or no possibilities (in case no germ cells were found). Outcomes were compared between subgroups and logistic regression analyses were used to assess the association between the duration of hormonal treatment and the possibilities for fertility preservation. MAIN RESULTS AND THE ROLE OF CHANCE: Mature spermatozoa were encountered in 4.7% of orchiectomy specimens, all from transgender women who had initiated medical treatment in Tanner stage 4 or higher. In 88.3% of the study sample orchiectomy specimens only contained immature germ cells (round spermatids, spermatocytes or spermatogonia, as most advanced germ cell type). In 7.0%, a complete absence of germ cells was observed, all these samples were from transgender women who had initiated medical treatment in adulthood. Cessation of hormonal treatment prior to gGAS did not affect the presence of germ cells or their maturation stage, nor was there an effect of the duration of hormonal treatment prior to gGAS. LIMITATIONS, REASONS FOR CAUTION: Since data on serum hormone levels on the day of gGAS were not available, we were unable to verify if the transgender women who were asked to temporarily stop hormonal treatment 4 weeks prior to surgery actually did so, and if people with full spermatogenesis were compliant to treatment. WIDER IMPLICATIONS OF THE FINDINGS: There may still be options for fertility preservation in orchiectomy specimens obtained during gGAS since a small percentage of transgender women had full spermatogenesis, which could enable cryopreservation of mature spermatozoa via a testicular sperm extraction procedure. Furthermore, the vast majority still had immature germ cells, which could enable cryopreservation of testicular tissue harboring spermatogonial stem cells. If maturation techniques like in vitro spermatogenesis become available in the future, harvesting germ cells from orchiectomy specimens might be a promising option for those who are otherwise unable to have biological children. STUDY FUNDING/COMPETING INTEREST: None. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. de Nie I, Mulder CL, Meißner A, et al. Histological study on the influence of puberty suppression and hormonal treatment on developing germ cells in transgender women. Hum Reprod. 2022. PMID: 34791270. doi:10.1093/humrep/deab240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。